Xenetic Biosciences Stock Fundamentals
| XBIO Stock | USD 4.01 0.02 0.50% |
Xenetic Biosciences fundamentals help investors to digest information that contributes to Xenetic Biosciences' financial success or failures. It also enables traders to predict the movement of Xenetic Stock. The fundamental analysis module provides a way to measure Xenetic Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xenetic Biosciences stock.
At this time, Xenetic Biosciences' Interest Income is very stable compared to the past year. Xenetic | Select Account or Indicator |
Xenetic Biosciences Company Shares Outstanding Analysis
Xenetic Biosciences' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Xenetic Biosciences Shares Outstanding | 1.54 M |
Most of Xenetic Biosciences' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xenetic Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Xenetic Shares Outstanding Historical Pattern
Today, most investors in Xenetic Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Xenetic Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Xenetic Biosciences shares outstanding as a starting point in their analysis.
Xenetic Biosciences Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Xenetic Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Xenetic Biosciences has 1.54 M of shares currently outstending. This is 99.15% lower than that of the Biotechnology sector and 98.56% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 99.73% higher than that of the company.
Xenetic Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Xenetic Biosciences's current stock value. Our valuation model uses many indicators to compare Xenetic Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Xenetic Biosciences competition to find correlations between indicators driving Xenetic Biosciences's intrinsic value. More Info.Xenetic Biosciences is rated second in return on equity category among its peers. It is rated fourth in return on asset category among its peers . At this time, Xenetic Biosciences' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Xenetic Biosciences' earnings, one of the primary drivers of an investment's value.Xenetic Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xenetic Biosciences' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Xenetic Biosciences could also be used in its relative valuation, which is a method of valuing Xenetic Biosciences by comparing valuation metrics of similar companies.Xenetic Biosciences is currently under evaluation in shares outstanding category among its peers.
Xenetic Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Xenetic Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Xenetic Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Xenetic Fundamentals
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (1.86) % | ||||
| Operating Margin | (1.84) % | ||||
| Current Valuation | (684.62 K) | ||||
| Shares Outstanding | 1.54 M | ||||
| Shares Owned By Insiders | 19.05 % | ||||
| Shares Owned By Institutions | 2.09 % | ||||
| Number Of Shares Shorted | 14.83 K | ||||
| Price To Earning | (1.81) X | ||||
| Price To Book | 0.87 X | ||||
| Price To Sales | 2.46 X | ||||
| Revenue | 2.54 M | ||||
| Gross Profit | 1.16 M | ||||
| EBITDA | (4.52 M) | ||||
| Net Income | (4.13 M) | ||||
| Cash And Equivalents | 14.93 M | ||||
| Cash Per Share | 1.04 X | ||||
| Total Debt | 809.59 K | ||||
| Current Ratio | 12.02 X | ||||
| Book Value Per Share | 6.36 X | ||||
| Cash Flow From Operations | (4.11 M) | ||||
| Short Ratio | 0.77 X | ||||
| Earnings Per Share | (2.66) X | ||||
| Target Price | 40.0 | ||||
| Beta | 2.26 | ||||
| Market Capitalization | 6.19 M | ||||
| Total Asset | 10.61 M | ||||
| Retained Earnings | (193.23 M) | ||||
| Working Capital | 8.78 M | ||||
| Current Asset | 1.21 M | ||||
| Current Liabilities | 4.97 M | ||||
| Net Asset | 10.61 M |
About Xenetic Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xenetic Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xenetic Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xenetic Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -24.3 K | -23.1 K | |
| Total Revenue | 2.5 M | 1.6 M | |
| Cost Of Revenue | 31.1 K | 29.5 K | |
| Stock Based Compensation To Revenue | 0.11 | 0.11 | |
| Sales General And Administrative To Revenue | 1.40 | 1.33 | |
| Research And Ddevelopement To Revenue | 1.38 | 1.31 | |
| Capex To Revenue | 0.34 | 0.18 | |
| Revenue Per Share | 1.66 | 1.58 | |
| Ebit Per Revenue | (1.78) | (1.87) |
Pair Trading with Xenetic Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Xenetic Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xenetic Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving against Xenetic Stock
The ability to find closely correlated positions to Xenetic Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xenetic Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xenetic Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xenetic Biosciences to buy it.
The correlation of Xenetic Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Xenetic Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Xenetic Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Xenetic Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Xenetic Biosciences Piotroski F Score and Xenetic Biosciences Altman Z Score analysis. To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenetic Biosciences. If investors know Xenetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenetic Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Revenue Per Share 1.638 | Quarterly Revenue Growth 0.116 | Return On Assets (0.29) | Return On Equity (0.49) |
The market value of Xenetic Biosciences is measured differently than its book value, which is the value of Xenetic that is recorded on the company's balance sheet. Investors also form their own opinion of Xenetic Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Xenetic Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenetic Biosciences' market value can be influenced by many factors that don't directly affect Xenetic Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenetic Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenetic Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenetic Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.